# Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct06739044` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06739044](<https://clinicaltrials.gov/study/NCT06739044>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06739044

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.

## Technical summary

Registry record NCT06739044. Randomized; no masking; primary purpose treatment. Start 2023-09-20 (actual); primary completion 2024-10-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 494 participants (enrolled count; ClinicalTrials.gov record NCT06739044, source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)
- Started: 2023-09-20 (actual) (ClinicalTrials.gov record NCT06739044, source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)
- Primary completion: 2024-10-11 (actual) (ClinicalTrials.gov record NCT06739044, source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)
- Completion: 2025-02-21 (actual) (ClinicalTrials.gov record NCT06739044, source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06739044, source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06739044-2025-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Ozempic®
- Intervention (Drug): HDG1901
- Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide injection for diabetes (Ozempic) (`cardio:ozempic`)
- Registry lists this organization as the lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (`cardio:org-hangzhou-zhongmei-huadong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 192cd08dd937536df0c60de0b9e1c870f3c7083925a3dc046e6a441bfdc6bbda
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
